Guanfacine to reduce heavy drinking in adults with alcohol use disorder
Part of Mental health clinical trials.
This Phase 2 study tests whether guanfacine can reduce drinking in women and men who drink heavily and meet criteria for alcohol use disorder. It also looks at how the medicine affects drinking patterns in a controlled setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 21 and 70 years old.
- You can read and write English.
- You meet criteria for alcohol use disorder based on your drinking over the last 6 months, including heavy daily drinking patterns for at least 30 days before the study.
- You can take pills by mouth, can follow the medication schedule, and are willing to cut down on drinking during treatment.
- You agree not to use certain drugs right before starting (including some anxiety and antidepressant medicines in the last 30 days and any illegal drugs).
- You must not be pregnant or nursing, and must use birth control (if applicable). Only one person per household can join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a brief medication approach meant to reduce “problem drinking.” It may help people cut back or stop alcohol use by adjusting brain signaling related to drinking cravings and urges.
This study tests whether the medication nimodipine (usually used for blood pressure) can help people who drink heavily reduce how much they drink. If you join, you may receive the medication or a placebo (a pill with no active ingredient) and take part in drinking sessions to see how it affects you.
This study tests if a blood-pressure medicine called nimodipine can help people who drink heavily reduce their alcohol intake. The trial involves lab-based drinking sessions and brain scans to understand how the drug works on the brain.
This study tests whether a new medication called NTX-2001 can help people with alcohol use disorder drink less. Researchers will measure how the drug affects alcohol consumption and safety in adults aged 21–60.
This study tests if adding a medication called guanfacine and mindfulness meditation to standard buprenorphine treatment helps people with opioid use disorder. It looks at whether this combination can improve treatment outcomes and reduce opioid use.
This study tests whether a medication called disulfiram (Antabuse) can help people with alcohol use disorder (AUD) feel less anxious when they stop drinking. Researchers will also use brain scans (MRI) to look at how the brain changes during early abstinence.
Hear when a new Alcohol Use trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.